Delcath SystemsDCTH +2.25%70 PB Ratio is 4.04 as of Jul. 05, 2026, which is 24% below its 10-year median of 5.30. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.95 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Delcath Systems ranks worse than 74.62% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-05), Delcath Systems's share price is $13.20. Delcath Systems's Book Value per Share for the quarter that ended in Mar. 2026 was $3.27. Hence, Delcath Systems's PB Ratio of today is 4.04.
Warning Sign:
Delcath Systems Inc stock PB Ratio (=4.04) is close to 1-year high of 4.04.
The historical rank and industry rank for Delcath Systems's PB Ratio or its related term are showing as below:
DCTH'
s PB Ratio Range Over the Past 10 Years
Min: 1.95 Med: 5.3 Max: 73.47
Current: 4.04
During the past 13 years, Delcath Systems's highest PB Ratio was 73.47. The lowest was 1.95. And the median was 5.30.
DCTH's PB Ratio is ranked worse than 74.62% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs DCTH: 4.04
During the past 12 months, Delcath Systems's average Book Value Per Share Growth Rate was 36.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Delcath Systems was 81.70% per year. The lowest was -42.70% per year. And the median was 11.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Delcath Systems PB Ratio Related Terms
Delcath Systems PB Ratio Historical Data
* Premium members only.
The historical data trend for Delcath Systems's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Delcath Systems's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's PB Ratio distribution charts can be found below:
* The bar in red indicates where Delcath Systems's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Delcath Systems's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Delcath Systems (DCTH) has a PB Ratio of 4.04 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Delcath Systems and its competitors. This is 24% below median its historical median of 5.30. Over the past decade, Delcath Systems' PB Ratio has ranged from 1.95 to 73.47. According to the industry distribution chart, Delcath Systems ranks #588 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 74.6%.
Is Delcath Systems' PB Ratio too high?
Delcath Systems' current PB Ratio of 4.04 is 24% below median its 10-year median of 5.30. Over the past 10 years, this metric has ranged from a low of 1.95 to a high of 73.47. The Medical Devices & Instruments industry median PB Ratio is 2.07. Delcath Systems' value of 4.04 is 95.2% above this industry median. Based on the distribution chart, Delcath Systems ranks #588 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' PB Ratio compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #588 out of 788 companies for PB Ratio. This places Delcath Systems in the lower half of its industry. The industry median PB Ratio is 2.07. Delcath Systems' value of 4.04 is 95.2% above this benchmark. Historically, Delcath Systems' own PB Ratio has ranged from 1.95 to 73.47 over the past decade. While the company's 10-year median is 5.30 vs. the industry median of 2.07, Delcath Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delcath Systems's current PB Ratio of 4.04 is 95.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current PB Ratio is 4.04, which is 24% below median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.95, compared to a current price of $13.20 — trading 64.3% below its estimated fair value. The current PB Ratio is 4.04, which is 24% below median its 10-year median of 5.30 and 95.2% above the Medical Devices & Instruments industry median of 2.07. Delcath Systems' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Delcath Systems (DCTH), the current PB Ratio is 4.04 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $13.20 is trading 64.3% below its estimated GF Value™ of $36.95.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
PB Ratio: 4.04 (24% below median its 10-year median of 5.30)
GF Value™: $36.95 vs. price of $13.20 (64.3% below fair value)
Industry Position: 95.2% above the Medical Devices & Instruments median (#588 of 788)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score
Get the complete analysis for DCTH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
